Indoco Remedies Share Price Hits Over One–Month High After Announcing Partnership With UK Distributor
Indoco Remedies Ltd.'s share price surged 10% to over one–month high as the company announced it's collaboration with a UK–based pharmaceutical distributor. Indoco Remedies entered into a strategic distribution with Clarity Pharma UK, it said in an exchange filing on Monday.
The partnership with Clarity Pharma is significant for Indoco Remedies as it will launch 20 products over the next 18 months through the British pharmaceutical company in the UK market, the filing said.
Indoco Remedies will continue supplying all products under existing business–to–business partnership to its client, it said.
Clarity Pharma has over 25 years of experience in introducing products to market and now services over 4,000 primary healthcare customers, Indoco Remedies said.
In a separate exchange filing, the research–based Indian pharmaceutical company said it has received a GST show–cause notice from Hyderabad Commercial Tax Department. A potential demand of Rs 15.51 crore has been made for the GST liabilities, basis the details provided for the period from 2020-2021.
Indoco Remedies does not see the claim materialising, however. "In the opinion of the company and based on the legal advice, these claims are nontenable in law as per other judicial pronouncements."
Indoco Remedies Share Price Today

Indoco Remedies' share price rose 10.25% to Rs 355.00, the highest level since Oct. 1. It pared gains to trade 5.03% higher at Rs 338.20 apiece, as compared to 0.35% advance in the NSE Nifty 50.
The stock gained 11.15% in 12 months, and declined 14.39% on year-to-date basis. Total traded volume so far in the day stood at 26 times its 30-day average. The relative strength index was at 61.98.
Out of seven analysts tracking the company, two maintain a 'buy' rating, two recommend a 'hold' and three suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 7.2%
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.